Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including colon, esophageal, gastric, rectum, breast, biliary tract, stomach, head and neck, cervical, pancreas, renal cell, and carcinoid.
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease
- Conditions
- Actinic KeratosisOrgan or Tissue Transplant; Complications
- Interventions
- First Posted Date
- 2012-02-02
- Last Posted Date
- 2022-03-15
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 18
- Registration Number
- NCT01525329
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
PD-0332991, 5-FU, and Oxaliplatin for Advanced Solid Tumor Malignancies
- Conditions
- Advanced Solid Tumor Malignancies
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2020-03-04
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 37
- Registration Number
- NCT01522989
- Locations
- 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
- Target Recruit Count
- 583
- Registration Number
- NCT01523431
- Locations
- 🇨🇳
Affiliated Hospital Cancer Center, Academy of Military Medical Sciences (307 Hospital of PLA), Beijing, Beijing, China
Colorectal Cancer (CRC) Cetuximab Elderly Frail
- Conditions
- Colorectal Cancer Metastatic
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2016-06-10
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 5
- Registration Number
- NCT01522612
- Locations
- 🇨🇾
Bank Of Cyprus Oncology Centre, Nicosia, Cyprus
🇧🇪AZ Turnhout - Campus Sint Elisabeth, Turnhout, Belgium
🇪🇸Hospital General Vall D'Hebron, Barcelona, Spain
Capecitabine in the Perioperative Treatment of Rectal Cancer
- First Posted Date
- 2011-12-29
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Universitätsmedizin Mannheim
- Target Recruit Count
- 401
- Registration Number
- NCT01500993
- Locations
- 🇩🇪
Dr Hans Walter Lindemann, Hagen, Germany
🇩🇪Dr Elisabeth Fritz, Koblenz, Germany
🇩🇪Prof Hartmut Link, Kaiserslautern, Germany
Phase I Study of 5-Fluorouracil in Children and Young Adults With Recurrent Ependymoma
- Conditions
- Central Nervous System MalignanciesEpendymoma
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2016-02-02
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 26
- Registration Number
- NCT01498783
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer
- Conditions
- Esophageal CancerAdenocarcinoma of the Gastroesophageal JunctionGastric Cancer
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2019-11-07
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 213
- Registration Number
- NCT01498289
- Locations
- 🇺🇸
Memorial Hospital, Carthage, Illinois, United States
🇺🇸Altru Cancer Center, Grand Forks, North Dakota, United States
🇺🇸Toledo Clinic Cancer Centers-Maumee, Maumee, Ohio, United States
Phase II Study of FOLFOXIRI in Patients With Locally Advanced or Metastatic Biliary Tract Cancer
- Conditions
- Biliary Tract Cancer
- First Posted Date
- 2011-12-19
- Last Posted Date
- 2011-12-19
- Lead Sponsor
- Soon Chun Hyang University
- Target Recruit Count
- 53
- Registration Number
- NCT01494363
- Locations
- 🇰🇷
Nam Su Lee, Seoul, Korea, Republic of
🇰🇷Han Jo Kim, Cheonan, Korea, Republic of
🇰🇷Hyun Jung Kim, Bucheon, Korea, Republic of
A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
- Conditions
- Colorectal Cancer
- Interventions
- First Posted Date
- 2011-12-13
- Last Posted Date
- 2019-09-24
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 70
- Registration Number
- NCT01490866
- Locations
- 🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States
🇺🇸NEA Baptist Clinic, Jonesboro, Arkansas, United States
🇺🇸Atlantic Health System, Summit, New Jersey, United States
Bevacizumab With Pelvic Radiotherapy And Primary Chemotherapy in Patients With Poor-Risk Rectal Cancer
- Conditions
- Rectal Cancer
- Interventions
- Radiation: Radiation therapyDrug: OxaliplatinDrug: RaltitrexedDrug: levofolinic acidDrug: 5-fluorouracilDrug: Bevacizumab
- First Posted Date
- 2011-11-29
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- National Cancer Institute, Naples
- Target Recruit Count
- 62
- Registration Number
- NCT01481545
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.